Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 14
2003 19
2004 21
2005 29
2006 36
2007 26
2008 28
2009 15
2010 30
2011 32
2012 39
2013 45
2014 28
2015 35
2016 38
2017 50
2018 56
2019 53
2020 70
2021 72
2022 62
2023 74
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Results by year

Filters applied: . Clear all
Page 1
Treprostinil.
[No authors listed] [No authors listed] 2021 Apr 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Apr 17. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000980 Free Books & Documents. Review.
One patient taking treprostinil breastfed her infant for one year without any complications. However, until more data are available, treprostinil should only be used with careful monitoring during breastfeeding....
One patient taking treprostinil breastfed her infant for one year without any complications. However, until more data are available, …
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Waxman A, et al. N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33440084 Clinical Trial.
RESULTS: A total of 326 patients underwent randomization, with 163 assigned to inhaled treprostinil and 163 to placebo. Baseline characteristics were similar in the two groups. ...There was a reduction of 15% in NT-proBNP levels from baseline with inhaled treprostinil …
RESULTS: A total of 326 patients underwent randomization, with 163 assigned to inhaled treprostinil and 163 to placebo. Baseline char …
Treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J, Habib N, Fann J, Radosevich JJ. Feldman J, et al. Future Cardiol. 2020 Nov;16(6):547-558. doi: 10.2217/fca-2020-0021. Epub 2020 May 11. Future Cardiol. 2020. PMID: 32391733 Review.
Recent developments revolve heavily around novel routes of drug administration and delivery. In 2009, inhaled treprostinil was approved followed by oral treprostinil in 2013 providing patients with more convenient routes of administration compared with the parentera …
Recent developments revolve heavily around novel routes of drug administration and delivery. In 2009, inhaled treprostinil was approv …
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, Feldman J, Hajari Case A, Argula RG, Tapson V, Smith P, Deng C, Shen E, Nathan SD. Waxman A, et al. Eur Respir J. 2023 Jun 29;61(6):2202414. doi: 10.1183/13993003.02414-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37080567 Free PMC article. Clinical Trial.
The open-label extension (OLE) evaluated long-term effects of inhaled treprostinil in PH-ILD. METHODS: Of 258 eligible patients, 242 enrolled in the INCREASE OLE and received inhaled treprostinil. ...CONCLUSIONS: These results support the long-term safety and effica …
The open-label extension (OLE) evaluated long-term effects of inhaled treprostinil in PH-ILD. METHODS: Of 258 eligible patients, 242 …
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Nathan SD, et al. Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. Lancet Respir Med. 2021. PMID: 34214475 Clinical Trial.
Treprostinil improved exercise capacity from baseline to week 16, assessed with the use of a 6-min walk test, compared with placebo. ...INTERPRETATION: In patients with ILD and associated pulmonary hypertension, inhaled treprostinil was associated with improvements …
Treprostinil improved exercise capacity from baseline to week 16, assessed with the use of a 6-min walk test, compared with placebo. …
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated …
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on cli …
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. McLaughlin VV, et al. J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027. J Am Coll Cardiol. 2010. PMID: 20430262 Free article. Clinical Trial.
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil. ...There were no improvements in other secondary end points, including time to clinical w …
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients rec …
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.
Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, Rischard F, Sahay S, Broderick M, Shen E, Smith P, Tapson VF, Waxman AB. Nathan SD, et al. Chest. 2023 Feb;163(2):398-406. doi: 10.1016/j.chest.2022.09.007. Epub 2022 Sep 15. Chest. 2023. PMID: 36115497 Free PMC article. Clinical Trial.
BACKGROUND: Pulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled treprostinil (iTre) has been shown to improve functional ability and to delay clinical worsening in patients with PH resulting from ILD. . …
BACKGROUND: Pulmonary hypertension (PH) complicates the course of many patients with fibrotic interstitial lung disease (ILD). Inhaled tr …
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension.
Spikes LA, Bajwa AA, Burger CD, Desai SV, Eggert MS, El-Kersh KA, Fisher MR, Johri S, Joly JM, Mehta J, Palevsky HI, Ramani GV, Restrepo-Jaramillo R, Sahay S, Shah TG, Deng C, Miceli M, Smith P, Shapiro SM. Spikes LA, et al. Pulm Circ. 2022 Apr 7;12(2):e12063. doi: 10.1002/pul2.12063. eCollection 2022 Apr. Pulm Circ. 2022. PMID: 35514770 Free PMC article.
A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil …
A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study wa …
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.
Kolb M, Orfanos SE, Lambers C, Flaherty K, Masters A, Lancaster L, Silverstein A, Nathan SD. Kolb M, et al. Adv Ther. 2022 Sep;39(9):3881-3895. doi: 10.1007/s12325-022-02229-8. Epub 2022 Jul 3. Adv Ther. 2022. PMID: 35781186 Free PMC article. Review.
In vitro and in vivo studies of PPARbeta and PPARgamma demonstrated that treprostinil inhibited fibroblast proliferation in a dose-dependent manner. ...These preclinical and clinical findings suggest a dual benefit of treprostinil through the amelioration of both lu …
In vitro and in vivo studies of PPARbeta and PPARgamma demonstrated that treprostinil inhibited fibroblast proliferation in a dose-de …
815 results